Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Colombo I, Genta S, Martorana F, Guidi M, Frattini M, Samartzis EP, Brandt S, Gaggetta S, Moser L, Pascale M, Terrot T, Sessa C, Stathis A. Colombo I, et al. Among authors: guidi m. Clin Cancer Res. 2021 Sep 15;27(18):5012-5019. doi: 10.1158/1078-0432.CCR-21-1402. Epub 2021 Jul 15. Clin Cancer Res. 2021. PMID: 34266890 Clinical Trial.
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso, Guidi M, Khoudour N, Pascaline Boudou-Rouquette, Fabre E, Tlemsani C, Arrondeau J, François Goldwasser, Vidal M, Schneider MP, Wagner AD, Widmer N, Blanchet B, Csajka C. Evelina Cardoso, et al. Among authors: guidi m. Clin Ther. 2020 Jul;42(7):1302-1316. doi: 10.1016/j.clinthera.2020.05.008. Epub 2020 Jul 4. Clin Ther. 2020. PMID: 32631634
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP. Bandiera C, et al. Among authors: guidi m. Cancers (Basel). 2023 Jan 3;15(1):316. doi: 10.3390/cancers15010316. Cancers (Basel). 2023. PMID: 36612312 Free PMC article.
Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use.
Dao K, Buettcher M, Golhen K, Kost J, Schittny A, Duthaler U, Atkinson A, Haefliger D, Guidi M, Bardinet C, Chtioui H, Boulekbache A, Buclin T, Huwyler J, Pfister M, Rothuizen LE. Dao K, et al. Among authors: guidi m. J Clin Pharmacol. 2024 Oct;64(10):1295-1303. doi: 10.1002/jcph.2462. Epub 2024 May 30. J Clin Pharmacol. 2024. PMID: 38813747 Clinical Trial.
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher JP, Chtioui H, Locatelli I, Decosterd LA, Darnaud L, Blanchet B, Alexandre J, Wagner AD, Zaman K, Schneider MP, Guidi M, Csajka C. Courlet P, et al. Among authors: guidi m. Pharmaceutics. 2022 Jun 21;14(7):1317. doi: 10.3390/pharmaceutics14071317. Pharmaceutics. 2022. PMID: 35890213 Free PMC article.
Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.
Ravix A, Bandiera C, Cardoso E, Lata-Pedreira A, Chtioui H, Decosterd LA, Wagner AD, Schneider MP, Csajka C, Guidi M. Ravix A, et al. Among authors: guidi m. Cancers (Basel). 2024 Jun 11;16(12):2193. doi: 10.3390/cancers16122193. Cancers (Basel). 2024. PMID: 38927898 Free PMC article.
367 results